Skip to main content

Advertisement

SpringerLink
Log in

Cutaneous Manifestations of Dermatomyositis and Their Management

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Dermatomyositis is a condition with pathognomonic and characteristic cutaneous lesions. This article describes the skin manifestations observed in patients with dermatomyositis, their differential diagnosis, their relationship to internal disease (particularly malignancy), and their management.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Callen JP, Wortmann RL: Dermatomyositis. Clin Dermatol 2006, 24:363–373.

    Article  PubMed  Google Scholar 

  2. • Antiochos BB, Brown LA, Li Z, et al.: Malignancy is associated with dermatomyositis but not polymyositis in northern New England, USA. J Rheumatol 2009, 36:2704–2710. This study demonstrates that the presence of skin disease is an important risk factor for the presence of malignancy.

    Article  PubMed  Google Scholar 

  3. Pachman LM, Abbott K, Sinacore JM, et al.: Duration of illness is an important variable for untreated children with juvenile dermatomyositis. J Pediatr 2006, 148:247–253.

    Article  PubMed  Google Scholar 

  4. • Bendewald MJ, Wetter DA, Li X, Davis MD: Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County, Minnesota. Arch Dermatol 2010, 146:26–30. This study demonstrated that amyopathic dermatomyositis occurs in about 20% of patients with dermatomyositis and that malignancy may occur in these patients as well.

    Article  PubMed  Google Scholar 

  5. Bohan A, Peter JB: Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975, 292:344–347.

    Article  CAS  PubMed  Google Scholar 

  6. Bohan A, Peter JB: Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975, 292:403–407.

    CAS  PubMed  Google Scholar 

  7. Dourmishev L, Meffert H, Piazena H: Dermatomyositis: comparative studies of cutaneous photosensitivity in lupus erythematosus and normal subjects. Photodermatol Photoimmunol Photomed 2004, 20:230–234.

    Article  CAS  PubMed  Google Scholar 

  8. Klein RQ, Bangert CA, Costner M, et al.: Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis. Br J Dermatol 2008, 159:887–894.

    Article  CAS  PubMed  Google Scholar 

  9. Kasteler JS, Callen JP: Scalp involvement in dermatomyositis. Often overlooked or misdiagnosed. JAMA 1994, 272:1939–1941

    Article  CAS  PubMed  Google Scholar 

  10. • Smith ES, Hallman JR, DeLuca AM, et al.: Dermatomyositis: a clinicopathological study of 40 patients. Am J Dermatopathol 2009, 31:61–67. This report demonstrates that although there are subtle histopathologic differences between lupus erythematosus and dermatomyositis, these changes are not useful in distinguishing lupus from dermatomyositis in clinical practice.

    Article  PubMed  Google Scholar 

  11. Magro CM, Crowson AN: The immunofluorescent profile of dermatomyositis: a comparative study with lupus erythematosus. J Cutan Pathol 1997, 24:543–552.

    Article  CAS  PubMed  Google Scholar 

  12. • Magro CM, Segal JP, Neil Crowson A, Chadwick P: The phenotypic profile of dermatomyositis and lupus erythematosus: a comparative analysis. J Cutan Pathol 2009 Nov 4 (Epub ahead of print). This study demonstrates subtle differences between dermatomyositis and lupus erythematosus, but this testing is not likely to be applicable in clinical practice.

  13. Sontheimer RD: Clinically amyopathic dermatomyositis: what can we now tell our patients? Arch Dermatol 2010, 146:76–80.

    Article  PubMed  Google Scholar 

  14. Hill CL, Zhang Y, Sigurgeirsson B, et al.: Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001, 357:96–100.

    Article  CAS  PubMed  Google Scholar 

  15. Lampropoulos CE, D’Cruz DP: Topical tacrolimus treatment in a patient with dermatomyositis. Ann Rheum Dis 2005, 64:1376–1377.

    Article  CAS  PubMed  Google Scholar 

  16. Woo TY, Callen JP, Voorhees JJ, et al.: Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine. J Am Acad Dermatol 1984, 10:592–600.

    Article  CAS  PubMed  Google Scholar 

  17. Ang GC, Werth VP: Combination antimalarials in the treatment of cutaneous dermatomyositis: a retrospective study. Arch Dermatol 2005, 141:855–859.

    Article  CAS  PubMed  Google Scholar 

  18. Pelle MT, Callen JP: Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus. Arch Dermatol 2002, 138:1231–1233.

    Article  PubMed  Google Scholar 

  19. Zieglschmid-Adams ME, Pandya A, Cohen SB, Sontheimer RD: The value of methotrexate in dermatomyositis. J Am Acad Dermatol 1998, 38:130–132.

    CAS  PubMed  Google Scholar 

  20. Edge JC, Outland JD, Dempsey JR, Callen JP: Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis. Arch Dermatol 2006, 142:65–69.

    Article  CAS  PubMed  Google Scholar 

  21. • Sangle VS, Sangle SR, D’Cruz DP: Leflunomide as a remission-maintaining therapy in difficult-to-treat dermatomyositis. Ann Rheum Dis 2008, 67:723. This is one of several case reports to suggest a place for this agent.

    Article  CAS  PubMed  Google Scholar 

  22. Sereda D, Werth VP: Improvement in dermatomyositis rash associated with the use of antiestrogen medication. Arch Dermatol 2006, 142:70–72.

    Article  PubMed  Google Scholar 

  23. Nadiminti U, Arbiser JL: Rapamycin (sirolimus) as a steroid-sparing agent in dermatomyositis. J Am Acad Dermatol 2005, 52(2 Suppl 1):17–19.

    Article  PubMed  Google Scholar 

  24. Dalakas MC, Illa I, Dambrosia JM, et al.: A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993, 329:1993–2000.

    Article  CAS  PubMed  Google Scholar 

  25. • Chung L, Genovese MC, Fiorentino DF: A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol 2007, 143:763–767. This report demonstrated moderate effects on the muscle disease but only limited response of the skin disease.

    Article  CAS  PubMed  Google Scholar 

Download references

Disclosure

Dr. Callen has served as a consultant for EOS Pharmaceutical Corp., Amgen, Centocor Ortho Biotech, Abbott Laboratories, and Celgene Corp.

Author information

Authors and Affiliations

  1. Division of Dermatology, University of Louisville School of Medicine, 310 East Broadway, Suite 200, Louisville, KY, 40202, USA

    Jeffrey P. Callen

Authors
  1. Jeffrey P. Callen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jeffrey P. Callen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Callen, J.P. Cutaneous Manifestations of Dermatomyositis and Their Management. Curr Rheumatol Rep 12, 192–197 (2010). https://doi.org/10.1007/s11926-010-0100-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-010-0100-7

Keywords

Search

Navigation